| 产品描述: | Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. |
| 靶点: |
CDK4;CDK6 |
| 体外研究: |
在接受肿瘤特异性 CD8+ T 细胞[5] 的小鼠中,Abemaciclib metabolite M18 hydrochloride 导致 T 细胞持久性和免疫记忆增加。 |
| 体内研究: |
Abemaciclib metabolite M18 hydrochloride 在健康受试者血浆中的 T1/2 为 43.1 小时。 Abemaciclib metabolite M18 hydrochloride 的主要作用机制是抑制视网膜母细胞瘤 (RB) 蛋白磷酸化并因此诱导细胞周期停滞。 |
| 参考文献: |
1. Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study. 2. Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1. 3. Palaniappan, et al. Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res. 2016-7-15; 76 (14_Supplement): CT153. 4. Goel S, et al. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018 Nov;28(11):911-925. |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.883 ml |
9.416 ml |
18.832 ml |
| 5 mM |
0.377 ml |
1.883 ml |
3.766 ml |
| 10 mM |
0.188 ml |
0.942 ml |
1.883 ml |
| 50 mM |
0.038 ml |
0.188 ml |
0.377 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |